Jim Cramer's top 10 things to watch in the stock market Wednesday
Jim Cramer’s “top 10 things to watch” covers July CPI (headline 3.4% YoY, core 2.5%), with 2-year Treasury yields moving lower. He also cites stock moves and analyst actions: CoreWeave up ~19% on results, Super Micro target boosts to $39, Aramark target to $71, Cardinal Health target raised, Intuitive Surgical upgraded, Palo Alto Networks target to $415, Novo Nordisk downgraded, and On Holding removed after guidance cuts.
How this was made
The 30-second read
Why it matters
The only market-wide primary datapoint cited is July CPI matching expectations, which is described as pushing the 2-year yield lower. Company-specific trading catalysts are mostly analyst actions (upgrades/downgrades/PT changes) and one stock’s reported results driving a same-morning surge.
Market read
Traders get a same-day rates read-through from CPI plus a basket of single-name catalysts that can drive pre-market positioning and intraday momentum.
What to watch
China tie concerns for Super Micro and competitive proof points for Novo’s oral obesity program could dominate price action even if near-term analyst targets rise.
Background
This is a CNBC “Top 10 things to watch” market wrap that mixes a CPI release read-through with multiple analyst rating/price-target changes and one stock-specific surge.
Ticker impact
CoreWeave is surging 19% after reporting a revenue beat, narrower losses, more capacity coming online, and growing backlog.
Likely continued volatility and upside bias while traders digest durability of Nvidia A100 contracts through 2029.
The article cites a same-morning surge and specific operational/financial drivers, but provides no new numeric guidance beyond the beat and loss narrowing.
Super Micro Computer shares are up over 8% premarket after a strong quarter and multiple price-target boosts from Citi and Barclays.
Short-term support from upgrades/targets, with potential pullbacks if China exposure fears reprice the risk premium.
The catalyst is concrete (strong quarter plus PT boosts), but the article does not add new company-specific guidance figures.
Aramark’s price target was raised by UBS after the food service provider posted a strong quarter, with data-center construction cited as a growth driver.
Moderately bullish bias as the market weighs the multiyear agreement and Nexus platform positioning.
The article provides the PT change and thesis, but lacks the underlying earnings numbers or agreement terms.
Cardinal Health’s price target was raised after it issued “amazing” initial fiscal 2027 earnings guidance, with the stock closing at an all-time high.
Potential continuation higher if traders treat the initial guidance as credible and durable; otherwise mean reversion risk after an all-time-high close.
The article explicitly attributes the PT raise to initial fiscal 2027 guidance, but does not quote the guidance figures.
Intuitive Surgical was upgraded to buy from hold by Oppenheimer, citing a more nuanced risk-reward and viewing U.S. competition as a non-factor.
Likely upward drift versus peers in the short term, with sensitivity to any counter-evidence on competitive impact.
The thesis is qualitative and the article does not provide new ISRG-specific operational metrics.
Palo Alto Networks’ price target was hiked by Citizens to $415 from $320 after analysts pointed to increased AI-driven threat demand.
Bullish bias while the market prices sustained AI-driven cybersecurity spending.
The article gives the PT change and rationale but no new PANW results, bookings, or guidance.
The article links CoreWeave’s durability theme to Nvidia chips, noting six-year-old Nvidia A100 chips are contracted out to 2029.
Limited incremental impact for NVDA itself since the catalyst is CoreWeave-focused, but sentiment could remain supportive.
NVDA is mentioned as a dependency in CoreWeave’s thesis, not as the issuer of new NVDA-specific news.
Novo Nordisk was downgraded to hold from buy by Berenberg, arguing further multiple expansion depends on maintaining oral obesity leadership over Eli Lilly.
Near-term downside or underperformance risk versus peers until oral obesity leadership evidence improves.
The downgrade is a concrete sell-side action with a specific competitive thesis, though no new clinical data is provided.
Market effects
Reinforces AI infrastructure and cybersecurity demand narratives, while oral obesity competition remains a key valuation debate.
Primarily US-listed single-name catalysts; macro CPI read-through affects rates-sensitive positioning broadly.
Novo Nordisk and Swiss On Holding highlight ongoing global healthcare and consumer demand sensitivity to guidance and competitive dynamics.
Counterpoint
Some of the bullish moves (CoreWeave, Super Micro, Palo Alto) may be sentiment-driven around Nvidia and AI capex narratives rather than new, quantified guidance.
Key entities
- companyCoreWeave
Surging 19% after revenue beat, narrower losses, more capacity, and growing backlog, with Nvidia chip durability as a key theme.
- companySuper Micro Computer
Up over 8% premarket after a strong quarter and Citi/Barclays price-target boosts, despite flagged China tie concerns.
- companyAramark
UBS raised its price target after a strong quarter, citing data-center construction and a multiyear agreement.
- companyCardinal Health
Price target raised after initial fiscal 2027 earnings guidance; stock closed at an all-time high.
- companyIntuitive Surgical
Upgraded to buy from hold by Oppenheimer, with competition risk viewed as non-factor.
